FORM	4
------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Response	s)											
1. Name and Address of Reporting Person – Young Richard A			2. Issuer Name an Syros Pharmaceu			0.0	ol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director 10% Owner				
(Last) C/O SYROS PHAR MEMORIAL DRIV		C DIC (00	3. Date of Earliest Transaction (Month/Day/Year) 09/15/2016							ther (specify belo	ow)	
(Street) CAMBRIDGE, MA 02139			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Execution Date, if	3. Transact Code (Instr. 8)		(A) or Disposed of (D)		of (D)	0 1	Ownership	7. Nature of Indirect Beneficial	
			(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	X /	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb	ber	6. Date Exer	rcisable and	7. Title and	l	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	tion	of		Expiration I	Date	Amount of D		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivati	ve	(Month/Day	/Year)	Underlying Sec		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Securitie	es	1		Securities		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acquire	d	(Instr. 3 an		d 4)		Owned	Security:	(Instr. 4)	
	Security					(A) or						Direct (D)			
						Dispose	d of						1	or Indirect	
						(D)							Transaction(s)		
						(Instr. 3,	, 4,						(Instr. 4)	(Instr. 4)	
						and 5)					1				
											Amount				
								Date	Expiration		or				
								Exercisable		Title	Number				
				C 1	* 7						of				
				Code	V	(A)	(D)				Shares				
Stock															
Option	¢ 10.50	00/15/2016				22 000		(1)	00/14/2026	Common Stock	22 000	¢ 0	22.000	D	
(right to	\$ 12.59	09/15/2016		А		22,000		<u>(1)</u>	09/14/2026	Stock	22,000	\$ 0	22,000	D	
buy)										21001					
cuj)															

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Young Richard A C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE, MA 02139	Х							

Signatures

/s/ Kyle Kuvalanka, as attorney-in-fact	09/16/2016
-**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly (1) installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Dr. Young's continued service as a director through each applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.